Reuters logo
BRIEF-Oragenics doses first patient in phase 2 clinical trial of AG013 for oral mucositis
August 31, 2017 / 11:33 AM / 3 months ago

BRIEF-Oragenics doses first patient in phase 2 clinical trial of AG013 for oral mucositis

Aug 31 (Reuters) - Oragenics Inc

* Oragenics doses first patient in phase 2 clinical trial of AG013 for oral mucositis

* Oragenics Inc - Completion and full results of phase 2 trial expected by end of 2018​

* Oragenics Inc - Expect to report preliminary data on initial 20 enrolled patients by end of 2017 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below